Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 20/20 | 0.77 |
| ▸ | BAZ2A | Q9UIF9 | 19/20 | 0.77 |
| ▸ | BRD9 | Q9H8M2 | 5/20 | 0.76 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.65 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.65 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.65 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | BRD2 | P25440 | 1/20 | 0.40 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19586201 | 1.00 | BAZ2B (0.77) | BAZ2BBAZ2ABRD9TRIM24TAF1L | |
| SCHEMBL24510745 | 0.84 | BAZ2B (1.00) | BAZ2BBAZ2ABRD9TRIM24TAF1L | |
| SCHEMBL24510616 | 0.84 | BAZ2B (0.72) | BAZ2BBAZ2ABRD9TRIM24TAF1L | |
| SCHEMBL23318444 | 0.82 | BAZ2B (0.79) | BAZ2BBAZ2ABRD9TRIM24TAF1L | |
| SCHEMBL29352262 | 0.79 | BAZ2B (1.00) | BAZ2BBAZ2ABRD9TRIM24TAF1L | |
| SCHEMBL22339997 | 0.79 | BAZ2B (1.00) | BAZ2BBAZ2ABRD9TRIM24TAF1L | |
| SCHEMBL20805573 | 0.71 | BAZ2B (0.79) | BAZ2BBAZ2ABRD9TRIM24TAF1L | |
| SCHEMBL7097918 | 0.68 | BAZ2B (0.46) | BAZ2BBAZ2ABRD9 | |
| SCHEMBL6801877 | 0.63 | PTGS2 (0.49) | BAZ2BBAZ2ABRD9 | |
| SCHEMBL26302103 | 0.62 | BAZ2B (0.75) | BAZ2BBAZ2ABRD9BRD4BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | Design Therapeutics, Inc. | 2024-05-23 | — | — | US | disclosed |
| EP-4259133-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022126000-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | MTPN, DMPK, MBNL1 | BAZ2B 560/4885BAZ2A 363/4885BRD9 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.